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Understanding the functional effect of Single Amino acid Substitutions (SAS), derived
from the occurrence of single nucleotide variants (SNVs), and their relation to disease
development is a major issue in clinical genomics. Despite the existence of several
bioinformatic algorithms and servers that predict if a SAS is pathogenic or not, they
give little or no information at all on the reasons for pathogenicity prediction and on
the actual predicted effect of the SAS on the protein function. Moreover, few actual
methods take into account structural information when available for automated analysis.
Moreover, many of these algorithms are able to predict an effect that no necessarily
translates directly into pathogenicity. VarQ is a bioinformatic pipeline that incorporates
structural information for the detailed analysis and prediction of SAS effect on protein
function. It is an online tool which uses UniProt id and automatically analyzes known and
user provided SAS for their effect on protein activity, folding, aggregation and protein
interactions, among others. We show that structural information, when available, can
improve the SAS pathogenicity diagnosis and more important explain its causes. We
show that VarQ is able to correctly reproduce previous analysis of RASopathies related
mutations, saving extensive and time consuming manual curation. VarQ assessment
was performed over a set of previously manually curated RASopathies (diseases that
affects the RAS/MAPK signaling pathway) related variants, showing its ability to correctly
predict the phenotypic outcome and its underlying cause. This resource is available
online at http://varq.qb.fcen.uba.ar/. Supporting Information & Tutorials may be found in
the webpage of the tool.
Keywords: variation diagnosis, bioinformatics, web server, single amino acid substitutions, single amino acid
substitutions classification, FoldX
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INTRODUCTION
The potential for genomics to contribute to clinical care has
long been recognized, and the clinical use of information about
a patient’s genome is rising. In this sense, precision medicine
initiatives for disease treatment and prevention that take into
account individual variability in genes are being implemented
worldwide. Single nucleotide variants (SNVs) that manifest as
protein variants are the best known and most important form
of variations in the genome, therefore a critical problem is to
understand how single amino acid substitutions (SAS) affect
protein function and protein interaction networks (Vidal et al.,
2011; Hu et al., 2016) leading to disease.
There are a several SAS effect predictors, most of them
perform a bioinformatic analysis and provide a pathogenicity
outcome or score, i.e., the propensity of a variant to be involved
on the development of a disease, something which is not
straightforward to determine. They are usually based on sequence
information, focusing on residue conservation and lacking a
structural viewpoint which has proven to be critical to identify
their effect (Kiel and Serrano, 2014). Moreover, even if they
incorporate structural data (Bromberg and Rost, 2007; De Baets
et al., 2012), usually they do not provide information that helps
the user to understand the molecular mechanisms underlying
their prediction, thus preventing a personal assessment. This
black box prediction is possibly rooted in the fact that proper
(structural) analysis of possible effects of a given variant is
time-consuming and requires expert handling of different tools,
thus preventing its wide applicability in clinical genomics. As
filtering algorithms allow researchers to identify a handful of
variants that are likely pathogenic, manual curation and careful
analysis are usually needed. Furthermore, even if a variant has
been identified, mainly because it has been previously associated
with disease, its molecular effect on protein function could still be
unknown.
Here, we present VarQ, a Web Server that automatically
analyzes several effects of SAS on protein function, particularly
protein folding, activity, protein-protein interactions, and drug
or cofactor binding. Analyzed variants are either automatically
extracted from clinical databases and/or can be submitted
directly by the user. VarQ automatically selects a critical set of
representative structural conformations of the desired protein
and diagnoses variants effect based on their impact. For this
sake several properties are computed for each variant, including
involvement in ligand binding, presence in the catalytic site
(Porter et al., 2004), presence in protein pockets using the
Fpocket software (Schmidtke et al., 2010), the free energy change
using FoldX (Schymkowitz et al., 2005), the residue sidechain
exposure to solvent, presence in a protein-protein interface
as identified in the corresponding protein-protein complex
structure and/or in the 3did database (Stein et al., 2009), the
conservation of each residue in the Pfam family (Bateman
et al., 2004), the switchability propensity using abSwitch software
(Diaz et al., 2014) and the aggregability factor using Tango
software (Fernandez-Escamilla et al., 2004). VarQ is intuitive,
user-friendly, and provides clinicians, biochemists, geneticist
and all professionals involved in personalized medicine with a
straightforward tool to annotate and analyze protein variants.
A detailed description of the programs and databases used is
given in the Web Site.
MATERIALS AND METHODS
Implementation of the Method as a
Bioinformatic Pipeline
The VarQ tool is built around a collection of structural analysis
tools tied together with the help of the workflow system Ruffus
(Goodstadt, 2010). Having as unique input a list of UniProt
(Magrane and UniProt Consortium, 2011) accession codes,
the pipeline performs all the calculation steps described in
Figure 1, parallelizing the acquisition of independent properties
to improve its computational performance. Accession codes
already computed are stored in a database to retrieve results
without re-computing (this option works only for database stored
substitutions and not for new user uploaded mutations).
A Web Server developed with the Bottle Python library1 allows
both to visualize the results and download them for further
analysis. Some of the features available are the mapping of the
found variants on the protein sequence (Figure 2) and structure
using JSmol (Hanson et al., 2013).
Structure Mining
When the user specifies a UniProt accession, the VarQ Pipeline
searches within all available structures mapped to the that
UniProt within the PDB database, that cover different segments
of the sequence, preferring those with highest coverage first and
those with the best resolution in second place as a tiebreaker.
Only those crystals covering at least 20 amino acids of the
sequence of the target protein are considered. If there is more
than one crystal structure covering the same part of the protein
sequence, but coupling with different ligands, then both will
be considered. If the same protein is crystallized in complex
with another protein they will be considered separately and will
appear with the information of the partner protein. The UniProt
database is requested online to list all available crystal structures.
If the protein has not resolved structures in the PDB, an error
message will be displayed in the web page together with 2 links
to aid the user to search for possible solutions to this problem:
one is the search of the UniProt accession in the RCSB web
page and the second is the search of all crystallized UniProt
accession codes that have the same gene name. No decisions are
automatically taken at this point since no homology modeling is
performed by the tool and sequence differences in homolog non
human proteins could lead to unexpected outcomes that have to
be considered by the user.
Variation Mining
For each UniProt accession analyzed, VarQ pipeline
automatically mines online for known variants. Actually,
there are several databases populated with variants coming
from different sources: clinical trials (Landrum et al., 2016),
1bottlepy.org
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FIGURE 1 | VarQ general pipeline. Each known structural conformation of the input protein is analyzed independently to aid the user in variant effect interpretation.
sequencing information (Forbes et al., 2011), user submission
(Day, 2010), etc. In this work, we are considering as a source of
variants the following databases: (i) UniProt annotated variants
coming from dbSNP and BioMuta databases. (ii) UniProt
curated variants for human genes, UniProt database provides a
database called humsavar (Famiglietti et al., 2014) that contains
qualitative information classifying for all listed variants if they
are disease-related or not and which is the disease involved
in each mutation. (iii) ClinVar variants provide additional
mutations coming from clinical studies. When a protein target
is introduced to our pipeline, all this information is downloaded
and the variations are kept for subsequent analysis.
Binding and Catalytic Residues
Each structure of the Protein Data Bank (PDB) provides as an
annotation for each crystallized ligand (compound, ion, cofactor,
etc.) A dataset of solvent molecules were built to consider as
binding residues only those interacting with non-solvents as
binding residues. The information is parsed directly by the
pipeline and the corresponding residues are labeled as involved
in binding.
Also, we used the FPocket software for each protein structure
considered in the analysis to calculate the protein pockets. We
only considered the pockets with Druggability Score greater than
0.5, and/or if a ligand is present in the pocket. All the residues
belonging to the pocket (even those not in contact with the
ligand) are considered as binding residues.
Catalytic Site Atlas (CSA) is a database documenting the active
sites and catalytic residues of enzymes. CSA contains 2 types
of entries: original manual-annotated entries, derived from the
primary literature and homology-determined entries, based on
sequence comparison methods to one of the original entries. All
the residues belonging to the CSA database are labeled as catalytic
residues in the VarQ pipeline.
Changes in Protein Stability
All mutations that were mapped to any protein structure were
analyzed with the FoldX software. The FoldX software predicts
the free energy change of a given mutation on the protein
stability or on the stability of a protein-protein complex, and
has been widely tested as an accurate predictor for point
mutations without the need of more time-consuming techniques
like Molecular Dynamics or Monte Carlo simulations (Guerois
et al., 2002). Mutagenesis was performed using the BuildModel
option of FoldX. The stabilities were calculated using the
Stability command of FoldX, and 11G values are computed
by subtracting the energy of the WT from that of the mutant.
The FoldX energy function includes terms that have been found
to be important for protein stability. The equation describing
the calculation of free energy of unfolding (1G) of a target
protein is described in detail in the FoldX web server. Briefly, it
consists of an empirical force field that estimates the difference
in the Van der Waals contributions of the protein with respect
to the solvent, the differences in solvation energy for apolar
and polar groups, the free energy difference between hydrogen
bond formation, the difference in electrostatic interactions and
the change in entropy due to fixing of the backbone and the
sidechain in the folded state. When protein-protein stability
is estimated, the empirical force field also includes a term
related to the change in translational and rotational entropy
and a term that takes into account the role of electrostatic
interactions on the association constant. Those mutations that
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FIGURE 2 | An Example of VarQ output for the HRAS gene (PDB id 3DDC). On top left, we show the structural features derived from crystallographic data. Target
gene and possible interacting genes are shown in green and gray respectively. Structural coverage, PFam family assignment and location of the variant are mapped
over the UniProt original sequence.
have more than 2 kcal/Mol 11G are labeled as “High 11G
variation.”
Residue Exposure
For each residue in each structure, the Solvent Accessible Surface
Area (SASA) was computed. Sidechain exposure percentages of
each residue are informed, and those with more than 50% of its
surface exposed are labeled as exposed, or on the contrary, as
buried. For this computation, the PyMol software (DeLano, 2002)
is used as a command line tool calling to the get_area feature.
The glycine residues are never labeled as buried or exposed since
always present a 0% of exposure because of its absence of a
sidechain. In the structural window, the value is displayed and
a horizontal bar chart is shown based on the total side chain
surface.
Protein-Protein Interfaces
In order to detect those mutations that can affect protein-protein
interaction, we decided to label the amino acids present in
protein-protein interaction surfaces. To label a residue belonging
to a protein-protein interface we evaluated the structures that
have more than one chain. When an atom of a residue of one
chain is at a distance of less than 5Å from an atom of the
other chain the residue is labeled as interface residue. We also
added an extra criteria; if the residue in the 3did database has
been labeled as interacting we labeled the residue as 3did but
we did not add the interface label. Despite the fact that the
3did database is not accurate enough for our automatic analysis
pipeline, we decided to add this information since we considered
it valuable to evaluate possible effects as it expands the database
of residues which are involved in protein-protein interfaces, but
needs manual inspection.
Other Properties
The B-factor of a residue usually relates to its mobility and
we inform this value with respect to the median of the
B-factor of all the residues in the protein. We also calculate the
Switchability, which informs the tendency of residues to switch
from alpha-helix to a beta sheet type of secondary structure; the
Aggregability, which is the tendency of a residue to generate
aggregation when is mutated and is computed using the Tango
Software; the conservation, calculated as the value in bits of the
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TABLE 1 | Comparison of mutation-mining of previous hand-curated work against





Total variants 956 1109
Mapped onto structure 624 566
Predicted to be neutral 197∗ 152
Predicted to be affect protein function 427∗ 414
∗ In Kiel and Serrano, 2014 variants were classified as neutral or disease causing
based on FoldX energy score.
TABLE 2 | Classification of the previous work (FoldX destabilizing/disease-causing
mechanism know category) compared with the automatic classification applied to
VarQ results.
Effect in Kiel and
Serrano, 2014
VarQ
Active site + Binding 200 (47%) 203 (49%)
Protein-protein interaction 79 (18%) 74 (18%)
Folding 145 (34%) 137 (33%)
Localization 3 (1%) –
Total 427 414
Our method do not label any mutation as “localization” so we kept the label used
by Kiel & Serrano. Number in parenthesis are the percentages of the total residues
with that label.
corresponding letter of the original amino acid in the Pfam family
only if it is assigned for the analyzed position. This value is
computed by an in-house developed script.
RESULTS
The Web Server is developed to run proteins based on its UniProt
ID. To test our developed pipeline we first run a manually
curated set of variants derived from our previous work (Kiel and
Serrano, 2014), comprising mutations in Ras/MAPK pathway
components which can cause either cancer or developmental
a group of disorders called RASopathies (Tidyman and Rauen,
2009). This previous case by case analysis required a considerable
amount of manual curation and now constitutes an excellent
benchmark for our web server capabilities. The results obtained
with the newly developed pipeline (Figure 1) as implemented
in the VarQ web server where all the calculations and
decisions run fully automatic are presented in Table 1. VarQ
automatically retrieved 566 variants, out of the 624 mutations
identified manually and structurally mapped by Kiel and Serrano
(Table 1).
In Figure 2 an example of the VarQ output for one of
the crystallographic configurations available for the HRAS gene
(PDB id 3DDC) is shown. It depicts the solved crystallographic
unit and the retrieved variations mapped into the protein
sequence. PFam family information is also shown. Each structural
configuration may produce for each variant a different outcome:
for example, bounded-to-ligand and unbounded crystals of
the same protein can figure lead to classify one position
as “Active site” for only one crystal, leading to another
outcome in the other crystal. To classify the variations on the
analyzed data set, the outcomes were applied to label each
variant following the criteria established in the columns of
Table 3, from left to right (i.e., one variation labeled as “Active
site” in one crystal is considered as Active site even if in
other crystals this position is not in bounded with a ligand
molecule).
Figure 3 shows the histogram of the 11G energy, estimated
using the FoldX software, for neutral and pathogenic SAS. As
clearly evidenced, a value higher than 2 kcal/mol is a good
indication that the SAS and thus, the underlying mutation is
likely to be pathogenic, However, for lower 11G energy values,
other properties need to be considered to be able to define
potential pathogenicity, and also to understand the underlying
molecular mechanism leading to disease.
VarQ pipeline, further classifies all the amino acids of each
protein automatically, in key categories related to their function
(being part of the active site, of protein-protein interaction
surfaces, etc. see section “Materials and Methods” for details) and
presents that information to help decision making (Table 3). For
example, we were able to identified 94% of the manual curated
protein-protein interaction variants; also all variants with high
switchability and aggregability, which were correctly classified as
folding disruptors.
The active site and binding residues are those either labeled
as ligand-binding residues in the PDB file, those belonging







Diagnostic Website Outcome Label
X Protein activity altered Disrupt protein function
× X Protein-protein interaction affected Disrupt protein interface
↑ × × X Destabilization of domain preventing folding Disrupt protein folding
× × × X Destabilization of domain preventing folding Disrupt protein structure
↓ X Potential protein activity altered Potential disruption protein function
× X Potential protein-protein interaction affected Potential disruption protein interface
× × X Potential destabilization of domain preventing folding Potential disruption protein folding
× × × X Potential destabilization of domain preventing folding Potential disruption protein structure
↓ × × × × × No effect Likely non pathogenic mutation
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FIGURE 3 | Change in folding energy (11G) computed by the FoldX software for all mined variants in analyzed RASopathies related proteins. Pathogenic and
non-pathogenic variants are shown separately.
to the same pocket of these residues as determined by the
Fpocket program, and those belonging to the CSA database.
For example, there are three HRAS structures, one bound
to GNP (i.e., PDB id 3DDC), other to GTP (i.e., PDB id
4K81) and another one with no ligand (i.e., PDB id 6AXG),
and reported mutations in the binding pocket have been
proposed to modify signaling cascades, which are involved in
different diseases (Prior et al., 2012). VarQ properly labeled
these residues as “active site residues” in each coupled structure
indicating the correct when corresponds, thus allowing the
user to rationalize SAS effects in those signaling pathways. For
the Glycine 12 the Clinvar database reports several disease
associated mutations, each one presenting different energies
according to the pose of the ligand, if present, and subsequently
to different outcomes that have to be pondered by the
user.
Folding residues are those that correspond to neither
inter-domain nor Active Site having an accessible surface area
percentage lower than 50%. In the particular case of the
RASopathies proteins, a high proportion of the residues are
marked as interface-involved because these proteins participate
in a very complex network with a large set of protein-protein
interactions. Localization mutations (a total of 3, see Table 2) are
not included in our analysis.
To summarize the value of the method, we were able to
automatically identify and predict as significantly affecting
protein function 414 (≈ 97% efficiency) of the 427 pathogenic
variants in the original data set, showing that structural
information can enrich the knowledge leading to SAS
pathogenicity prediction (see Figure 4).
DISCUSSION
In this work we introduce VarQ, a novel online tool that
offers an user friendly way to evaluate the effect of protein
variants that arise from human genomics projects. We have
FIGURE 4 | Receiver Operating Characteristic Curves for the diagnosis of Kiel
& Serrano manually curated pathogenic variants that were mapped into
structure. Pathogenic mutations are considered true positives in Clinvar (black
curve) data set when they are labeled as “pathogenic” or “likely pathogenic.”
For VarQ (green curve) true positives are considered for all the labels except
“no effect”.
shown that VarQ is able to correctly reproduce previous analysis
of RASopathies related mutations avoiding extensive and time
consuming manual curation. Also, we were able to assign 153
novel mutations that cannot be compared with the previous
study, a detailed outcome of this mutations is provided in
Supplementary Table S1.
Users can apply VarQ to either analyze mutations that
are already available in clinical databases or to analyze novel
unreported variants. To assist variation diagnosis each analyzed
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mutation is labeled according to several computed properties.
For different conformations of the same protein (i.e., active and
inactive determined structures) the same mutation could lead to
different labeling, leaving to the user the final assessment of the
effect caused by the variation. VarQ displays its full potential on
human proteins with known structure(s) but can also be used
with any protein. Usually clinical researchers, biochemists and
geneticists do not have the bioinformatic resources to massively
analyze variants so they use web servers or easy to use softwares to
classify the variants. On the other hand, bioinformatic softwares
usually are aimed at predicting only pathogenicity but do not give
information for the users to be able to gain insight and finally
decide the possible/potential effect of the mutation. Structural
information is often not available for reported mutations: for
the RASopathies analyzed proteins, a highly represented set on
the PDB, only 20.3% of the Clinvar mutations for this proteins
could be mapped into structure, 2103 vs. 427. When available, this
information contributes to our understanding of the molecular
basis of disease (see Figure 4). This information is of paramount
importance when pathogenic prediction is challenging. In this
sense, for example a mutation that disrupts a protein-protein
interaction may be pathogenic or could be benign depending on
the protein function and the biology of the interaction. To the
best of our knowledge this is the first application that provides
this information in an automatic, simple and intuitive way.
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